CRSwNP in the Specialty Setting: Targeting Reduced Patient Burden With Evolved Assessment and Treatment Strategies - Monday, March 24, 2025

To assist us in evaluating the effectiveness of this activity, please complete the following pretest in its entirety. At the end of this survey, you will be redirected to the Zoom meeting.

*1.Which of the following best describes your profession?(Required.)

MD/DO    

NP    

PA    

RN    

PharmD/RPh

Other (please specify)

*2.Which of the following best describes your specialty?(Required.)

Otolaryngology

Otolaryngic Allergy

Allergy/Immunology

Family Practice/Internal Medicine

Other (please specify)

*3.How confident are you in the management of patients with CRSwNP in your practice?   (Required.)

Very confident  

Confident  

Neutral  

Little confidence  

No confidence  

*4.A 38-year-old woman with perennial allergic rhinitis (fluticasone over the counter) and asthma controlled on medium-dose inhaled corticosteroids, presents to ENT on referral for endoscopic evaluation of suspected nasal polyps. Primary care evaluation revealed total IgE = 200 IU, BEC = 600 cells/μL, NCS = 2, loss of smell = 2, and SNOT-22 = 53. How would you categorize the severity of CRSwNP in this patient? (Required.)

Mild

Moderate

Severe

*5.Logan is a 50-year-old man with a 3-year history of CRSwNP. He underwent functional endoscopic sinus surgery (FESS) 2 years ago, is currently being treated with EDS-FLU nasal spray, and has undergone two courses of oral corticosteroids (OCS) in the past year. He presents for persistent loss of smell, facial pain, and rhinorrhea. His evaluation indicates an NPS = 5, NCS = 2, SNOT-22 = 59, Lund-MacKay Score = 12, and BEC = 500 cells/μL. What treatment would you recommend for him?(Required.)

A brief course of OCS and continue treatment plan

No change to treatment plan

Revision FESS

Trial of a biologic

*6.In a 2024 study, after cost, what was the second most commonly reported barrier to initiation of biologic therapy among patients with CRSwNP?(Required.)

Inability or lack of desire to administer medication

Intolerable side effects

Unfamiliar with, or fear of, medication

*7.The EPOS/EUFOREA 2023 update suggests evaluating five criteria, including nasal polyp size, reduced need for OCS, reduced impact of comorbidities, and improvements in quality of life and sense of smell to define response to a biologic treatment. A good to excellent response is achieved if how many criteria are met?(Required.)

0-2

2-3

4-5